NASDAQ · MOVE
Corvex, Inc.
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
Loading market information…
NASDAQ · AMIX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Autonomix Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Autonomix Medical, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$2.62. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Autonomix Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 11, 2025 |
| -$30.660.0% vs estimate |
| $0.00 |
| Q2 2025 | Nov 8, 2024 | -$51.87 | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$0.16-$0.00 (-2.42%)
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
$7.79-$3.69 (-32.14%)
Flora Growth Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.43% below the high.
$0.18-$0.00 (-2.67%)
KALA BIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$0.37-$0.01 (-1.53%)
Oragenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.99% below the high.
$1.90+$0.02 (+1.06%)
NanoVibronix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.83% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
